Showing results (1801-1810 of 1,909) with videos related to

Sort By:
Pageof 191
Cytotherapy|April 5, 2025
CD34-selected stem cell boost was an effective treatment for refractory poor hematopoietic reconstitution after haploidentical hematopoietic stem cell transplantationYun He, Rui Ma, Yuanyuan Zhang, et al.
Hepatology Communications|December 13, 2024
The gut microbiota-produced vitamin B6 mitigates alcohol-associated liver disease by attenuating hepatic oxidative stress damageHaiyuan Shen, Liangliang Zhou, Yuanru Yang, et al.
Military Medical Research|May 15, 2023
Artificial intelligence-driven radiomics study in cancer: the role of feature engineering and modelingYuan-Peng Zhang, Xin-Yun Zhang, Yu-Ting Cheng, et al.
Journal of the American Chemical Society|May 15, 2026
Ligand-Orchestrated Burst Nucleation Enables Ultrasmall Phase-Pure High-Entropy Nanoalloys with Active-Armor InterfacesRui Ma, Chongyuan Zhai, Ru-Yu Zhou, et al.
Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi|January 29, 2009
[Levels of transition on maternal transferred measles antibody in infants in 3 cities in China]Guo-zhang Xu, Rui Ma, Hong-jie Xu, et al.
Frontiers in Bioengineering and Biotechnology|December 26, 2025
Artificial intelligence-assisted organoid construction in congenital heart disease: current applications and future prospectsFang Chen, Hao-Yi Zhang, Yan-Long Wan, et al.
Parkinsonism & Related Disorders|September 24, 2024
Anemia, blood cell indices, genetic correlations, and brain structures: A comprehensive analysis of roles in Parkinson's disease riskChun-Yan Zuo, Xiao-Yan Hao, Meng-Jie Li, et al.
Brain Communications|May 21, 2025
Cardiovascular risk factors modulate the effect of brain imaging-derived phenotypes on ischaemic stroke riskYuan-Yuan Liang, Meng-Jie Li, Dong-Rui Ma, et al.
Communications Biology|November 20, 2021
Allelic variants of full-length VAR2CSA, the placental malaria vaccine candidate, differ in antigenicity and receptor binding affinityJonathan P Renn, Justin Y A Doritchamou, Bergeline C Nguemwo Tentokam, et al.
Journal of Hematology & Oncology|January 5, 2025
A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)Hua-Jun Chen, Hai-Yan Tu, Yanping Hu, et al.
Pageof 191